TxinnoBioscience Inc.

Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue. Tcino Bioscience Co., Ltd. has secured and built core platform technologies such as small molecule innovative anticancer drug (targeted anticancer drug/immunotherapy) pipeline, LIN/TMED, an innate immune anticancer drug evaluation technology, and Ba/F3 evaluation system, a kinase inhibitor evaluation technology. It is a KIST technology investment bio venture established in September. We are currently researching and developing three pipelines for RAS-related targeted anticancer drugs and two pipelines for innate immune anticancer drugs. Based on deep scientific understanding of targets and technologies, we aim to grow into a global company dedicated to develop new innovative medicines.